

Curriculum Vitae

Natasa Jenson, M.D.

Research Affiliation

Elligo Health Research, Inc., 2022- Present
11612 Bee Cave Road, Bldg. 1, Suites 100 & 150, Austin, TX 78738


Research Affiliation

Arkansas Center for Sleep Medicine, PLLC
11219 Financial Centre Parkway, Suite 101
Little Rock, AR 72211
(501) 553-9987
(501) 553-9986 FAX

Research Affiliation

Preferred Research Partners, Inc.
11219 Financial Centre Parkway, Suite 320
Little Rock, AR 72211
(501) 553-9987
(501) 553-9986 FAX

Signature: _____



Date: _____

8-31-2022

Natasa Jenson, MD
Diplomate of American Board of Emergency Medicine
(805) 279-5338
ncjenson4@gmail.com
Active Oregon Medical License
Active DEA License
01/21/2018

EMPLOYMENT

Emergency Medicine Physician CHI St Vincent Little Rock, AR	2019- Current
Emergency Medicine Physician Conway Regional Medical Center Conway, AR	2018- Current
Emergency Medicine Physician CHI St Vincent Hot Springs, AR	2018- Current
Emergency Medicine Physician Sky Lakes Medical Center Klamath Falls, OR	2014 - 2018
Resident Physician Emergency Medicine Department Loma Linda, CA	2011 - 2014

EDUCATION

Resident Physician Loma Linda University Medical Center Emergency Medicine Department Loma Linda, CA	2011 - 2014
Loma Linda University School of Medicine Loma Linda, CA Doctor of Medicine	2007 - 2011
Andrews University Berrien Springs, MI BS, Biology	2006 - 2007
Southwestern Michigan College Dowagiac, MI Completed basic science courses	2004 - 2006

University of Zagreb School of Medicine
Zagreb, Croatia

2003 - 2004

RESEARCH PROJECTS AND PUBLICATIONS

- Diagnosis of Necrotizing Fasciitis with Bedside
Ultrasound – the *STAFF* exam** 8/2013
Authors: Erik Castleberg, MD; Natasa Jenson, MD
Vi Am Dinh, MD, RDMS, RDCS
Western Journal of Emergency Medicine; 2013.8.18303
<http://escholarship.org/uc/item/638584rd?view=search>
- Quality Improvement Project: ‘Goal of administering
aspirin to patients presenting with acute coronary syndrome
within 24 hours of arrival to the emergency department’** 2012 - 2014
Loma Linda Department of Emergency Medicine
- Quantifying xanthine oxidase levels in newborns
as a predictor of hypoxic brain injury outcomes.** 2006
Research project with principal Investigator Dr. Danilo Boskovic, PhD
Loma Linda University Department of Biochemistry and Physiology.
-

TEACHING AND PROFESSIONAL DEVELOPMENT

- Medical School Lectures**
Loma Linda School of Medicine
- Cardiopulmonary Arrest 6/2014
Approach to Trauma 6/2014
- Department Lectures:**
- Oropharyngeal Cancers 1/2013
Sudden Cardiac Arrest in Children 12/2012
Dermatologic Conditions, a Case Presentation 8/2012
Medical Response to Terrorism Training/Simulation Lab 5/2012
Tension Pneumothorax, a Case Presentation 10/2011
- Guest Lectures**
Neonatal Resuscitation 11/2012
- Journal Club Presentation:**
- Missed and Delayed Diagnoses in the Emergency Department: 8/2013
A Study of Closed Malpractice Claims From 4 Liability Insurers
Outpatient treatment of patients with acute 6/2013
pulmonary embolism: the Hestia Study
-

PROFESSIONAL ASSOCIATION MEMBERSHIPS

Alpha Omega Alpha Honor Medical Society	2010 - Present
American College of Emergency Physicians	2010 - Present

LEADERSHIP

Sepsis Treatment Improvement Project Sky Lakes Medical Center Klamath Falls, OR	2017 - Current
Emergency Medicine Interest Group Vice President Loma Linda University School of Medicine	2010 - 2011

References available upon request.

Research Experience

Pharmaceutical:

- 2019: Apnimed – Obstructive Sleep Apnea – APN-002
- 2019: Aptinyx – Post-Traumatic Stress Disorder – NYX-783-2004
- 2019: Biohaven Pharmaceuticals – Obsessive Compulsive Disorder – BHV4157-202
- 2019: Otsuka Pharmaceuticals – Post Traumatic Stress Disorder – 331-201-00071
- 2019: Takeda – Obstructive Sleep Apnea – Phase 1 – TAK-925-2001
- 2019: LG Chem – Gout with Hyperuricemia – LG-GDCL002
- 2019: Applied Therapeutics - Diabetic Cardiomyopathy / Stage B Heart Failure at High Risk of Progression to Overt Heart Failure (Stage C Heart Failure) – AT-001-2001
- 2019: Adare Pharmaceuticals – Eosinophilic Erosive Esophagitis – SP-1011-003
- 2019: Allergan - Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis – 3152-301-002
- 2019: Allergan – Constipation in Children 6-17 y/o – LIN-MD-64
- 2019: Allergan – Pediatric Participants with Functional Constipation (FC) or Irritable Bowel Syndrome with Constipation (IBS-C) – LIN-MD-66
- 2019: Allergan - Pediatric Participants (Age 2 to 5 Years) with Functional Constipation – LIN-MD-67
- 2019: Braintree Laboratories - Bowel Prep for Colonoscopy – BLI4900-302
- 2019: Phathom Pharmaceuticals – Erosive Esophagitis – EE-301
- 2019: Phathom Pharmaceuticals – H. Pylori – HP-301
- 2019: Vanda Pharmaceuticals – Diabetic or Idiopathic Gastroparesis – VP-VLY-686-3301
- 2019: Vibrant Ltd – Chronic Idiopathic Constipation – V270
- 2020: Takeda – Idiopathic Hypersomnia – Phase 1 – TAK-925-2002
- 2020: Neurogastrx – Diabetic or Idiopathic Gastroparesis – NG101-201

- 2020: Allergan – Major Depressive Disorder – 2006-308-008
- 2020: Otsuka – Pediatric Attention Deficit Hyperactivity Disorder – 405-201-00010
- 2020: Apnimed – Obstructive Sleep Apnea – APN-006
- 2020: Janssen – Treatment-resistant Depression – 54135419TRD4005
- 2020: Janssen – Major Depression & Insomnia – 42847922MDD3002
- 2020: Novavax – COVID-19 Vaccine – 2019nCoV-301
- 2020: Supernus – ADHD in Preschoolers – 812P401
- 2021: Otsuka Pharmaceuticals – ADHD in Children – 405-201-00046
- 2021: Apnimed – Obstructive Sleep Apnea – APC-003
- 2021: Apnimed – Obstructive Sleep Apnea – APC-003-OLE
- 2021: Moderna – CMV Vaccine – mRNA-1647-P301
- 2021: Acerus Pharmaceuticals – Ambulatory BP monitoring in Hypogonadism – NAT-2020-01
- 2021: Purdue Pharma LP – ADHD in Preschoolers & Children – ADA4004
- 2021: Apnimed – Obstruction Sleep Apnea – APC-005